Enhanced Composition for Promoting FGF21 Secretion
Legal Citation
Summary of the Inventive Concept
This inventive concept discloses improved compositions and methods for promoting the secretion of fibroblast growth factor 21 (FGF21), addressing the limitations of the original patent by enhancing efficacy, reducing dosage, and providing real-time monitoring.
Background and Problem Solved
The original patent relates to a composition for promoting the secretion of FGF21, but it has inherent limitations, such as variable efficacy and potential high dosages. The present inventive concept solves these problems by introducing novel combinations of Bifidobacterium bacterium with prebiotics, probiotics, or nutrients, and by developing sustained-release formulations and real-time monitoring systems.
Detailed Description of the Inventive Concept
The inventive concept comprises four main aspects: (1) a system combining Bifidobacterium bacterium with a prebiotic to enhance growth and FGF21 secretion; (2) a method of enhancing efficacy by co-administering the composition with a probiotic; (3) a composition comprising Bifidobacterium bacterium and a nutrient to enhance FGF21 gene expression; and (4) a sustained-release formulation and real-time monitoring system to reduce dosage and optimize treatment. These innovations address the limitations of the original patent and provide more efficient and effective solutions.
Novelty and Inventive Step
The new claims introduce novel combinations of components and methods that are not obvious from the original patent. The use of prebiotics, probiotics, and nutrients to enhance FGF21 secretion, as well as the development of sustained-release formulations and real-time monitoring systems, constitutes a significant inventive step beyond the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include different types of prebiotics, probiotics, or nutrients, as well as varying formulations and delivery methods. Additionally, the inventive concept could be adapted for use in different applications, such as food products or pharmaceuticals.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the fields of nutrition, pharmaceuticals, and healthcare, particularly in the development of treatments for metabolic disorders and other conditions related to FGF21 secretion.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Microbiome and Probiotic Biotechnology, specifically focused on bacterial compositions for metabolic and physiological modulation, requiring expertise in microbiology, nutritional science, and biotechnological formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A researcher or biotechnologist with advanced degree in microbiology or related field, familiar with probiotic strain characterization, metabolic pathway interactions, and formulation strategies for bacterial compositions
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core concept of using Bifidobacterium breve M-16V for physiological modulation. The proposed modifications involving prebiotics, nutrient enhancement, and monitoring systems represent standard optimization strategies within probiotic research. These variations would be considered routine experimental approaches for improving bacterial composition efficacy and delivery.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,579 |
|---|---|
| Title | Composition for promoting the secretion of FGF21 |
| Assignee(s) | Morinaga Milk Industry Co., Ltd. |